Traders Sell Shares of Emergent Biosolutions (EBS) on Strength (EBS)

Investors sold shares of Emergent Biosolutions Inc (NYSE:EBS) on strength during trading hours on Monday. $4.63 million flowed into the stock on the tick-up and $11.80 million flowed out of the stock on the tick-down, for a money net flow of $7.17 million out of the stock. Of all stocks tracked, Emergent Biosolutions had the 29th highest net out-flow for the day. Emergent Biosolutions traded up $0.38 for the day and closed at $52.08

EBS has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “strong-buy” rating and set a $48.00 target price on the stock in a research note on Tuesday, November 28th. Chardan Capital upped their target price on shares of Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. Goldman Sachs initiated coverage on shares of Emergent Biosolutions in a research note on Wednesday, January 24th. They issued a “neutral” rating and a $55.00 target price on the stock. Singular Research upped their target price on shares of Emergent Biosolutions from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Finally, ValuEngine raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $52.80.

How to Become a New Pot Stock Millionaire

The company has a market capitalization of $2,558.87, a P/E ratio of 30.82, a price-to-earnings-growth ratio of 1.01 and a beta of 1.26. The company has a current ratio of 4.85, a quick ratio of 3.42 and a debt-to-equity ratio of 0.01.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, February 22nd. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.70 by $0.04. The business had revenue of $193.80 million for the quarter, compared to analysts’ expectations of $189.96 million. Emergent Biosolutions had a net margin of 14.73% and a return on equity of 13.66%. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.74 earnings per share. equities research analysts expect that Emergent Biosolutions Inc will post 2.33 EPS for the current year.

In other Emergent Biosolutions news, EVP Adam Havey sold 5,842 shares of the business’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $52.82, for a total value of $308,574.44. Following the transaction, the executive vice president now directly owns 35,756 shares in the company, valued at $1,888,631.92. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jerome M. Hauer sold 5,152 shares of the business’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $50.91, for a total transaction of $262,288.32. Following the completion of the transaction, the director now owns 23,797 shares in the company, valued at $1,211,505.27. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,798 shares of company stock worth $1,714,330. Company insiders own 16.50% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Xact Kapitalforvaltning AB acquired a new position in Emergent Biosolutions in the fourth quarter valued at about $265,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp boosted its position in Emergent Biosolutions by 73.1% in the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 22,500 shares of the biopharmaceutical company’s stock valued at $1,046,000 after buying an additional 9,500 shares in the last quarter. MetLife Investment Advisors LLC acquired a new position in Emergent Biosolutions in the fourth quarter valued at about $730,000. Municipal Employees Retirement System of Michigan boosted its position in Emergent Biosolutions by 20.9% in the fourth quarter. Municipal Employees Retirement System of Michigan now owns 15,930 shares of the biopharmaceutical company’s stock valued at $740,000 after buying an additional 2,750 shares in the last quarter. Finally, Clark Capital Management Group Inc. boosted its position in Emergent Biosolutions by 40.1% in the fourth quarter. Clark Capital Management Group Inc. now owns 77,245 shares of the biopharmaceutical company’s stock valued at $3,590,000 after buying an additional 22,103 shares in the last quarter. Hedge funds and other institutional investors own 81.54% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Traders Sell Shares of Emergent Biosolutions (EBS) on Strength (EBS)” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2018/03/19/traders-sell-shares-of-emergent-biosolutions-ebs-on-strength-ebs.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply